<DOC>
	<DOC>NCT01040871</DOC>
	<brief_summary>This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Non-Germinal Center B-Cell (non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)</brief_summary>
	<brief_title>Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Male or female patients 18 years or older. Newly Diagnosed nonGCB subtype of DLBCL (Stage II, III or IV). At least 1 measurable site of disease. Eastern Cooperative Oncology Group (ECOG) performance status 02 Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry and throughout the study; and have a negative pregnancy test at screening. Male subjects must agree to use a double barrier method of birth control Prior treatment with VELCADE. Prior extended radiotherapy or chemotherapy for lymphoma More than 150 mg/m2 of prior doxorubicin Major surgery within 3 weeks of study. Peripheral neuropathy or neuralgia of Grade 2 or worse. Active CNS lymphoma Diagnosed or treated for a malignancy other than NHL, with some exceptions Pregnant or breast feeding Active systemic infection Documented of suspected human immunodeficiency virus (HIV)/AIDS Uncontrolled or severe cardiovascular disease Known allergies, hypersensitivity or intolerance to study drugs Serious medical condition that could interfere with study Concurrent treatment with another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>